The ability to predict whether cancer treatment is working before surgery could transform patient outcomes and spare ineffective therapy exposure. Traditional imaging often fails to reveal the true extent of tumor destruction, leaving oncologists to make critical decisions with incomplete information.
In a study of 39 lung cancer patients receiving pre-surgical immunotherapy plus chemotherapy, researchers found that counting specific tumor cells circulating in blood provided superior prediction of treatment failure compared to standard imaging alone. Patients with higher levels of cytokeratin-positive circulating tumor cells (CK+ CTCs) were significantly less likely to achieve major pathological response, with this blood biomarker achieving 75.7% accuracy in identifying non-responders. When combined with imaging data, predictive accuracy improved to 79%, representing a meaningful clinical advantage over imaging alone.
This finding addresses a critical gap in precision oncology, where treatment decisions currently rely heavily on radiographic assessments that can miss microscopic disease persistence. The 38.5% major response rate observed aligns with published immunotherapy outcomes, but the ability to identify the 61.5% of non-responders earlier could prevent unnecessary surgical delays and treatment toxicity. The molecular profiling component suggests that tumor cell shedding patterns reflect deeper biological processes within the cancer microenvironment, potentially opening new therapeutic targeting opportunities. While promising, this single-institution study requires validation in larger, multi-center cohorts before clinical implementation, and the optimal timing and frequency of CTC monitoring remains undefined.